VWF (von Willebrand Factor) Drug Discovery Landscape & Assay Solutions
- By admin
- 04 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VWF-targeted drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (A1 Domain) | VWF A1 Domain Recombinant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). For GPIb binding assays. | View VWF Products |
| Antigen (A3 Domain) | VWF A3 Domain Recombinant Protein. Collagen-binding domain. Theoretical MW verified by Mass Spec. For extracellular matrix interaction studies. | View VWF Products |
| Antigen (Full-length ECD-Fc) | VWF ECD-Fc / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View VWF Products |
| Biomarker (VWFpp) | VWFpp (Propeptide) Recombinant Protein. Sequence Verified. Distinct from mature VWF for quantitative ELISA standards. | View VWFpp Products |
| Gene Delivery | VWF Lentivirus Particles. Full-length ORF for stable cell line construction. Endotoxin Controlled. For multimerization studies. | View VWF Products |
| Benchmark Ab | Anti-VWF Nanobody (Caplacizumab Biosimilar Sequence). Recombinant positive control targeting A1 domain. Sequence Verified. | View VWF Products |
| Validator | VWF siRNA Set. For knockdown verification in HUVEC or engineered cell lines. | View VWF Products |
| Related Target: ADAMTS13 | ADAMTS13 Protease. Essential for VWF multimer cleavage assays. | View ADAMTS13 Products |
| Related Target: FVIII | Factor VIII. Circulates in complex with VWF; critical for Hemophilia A therapeutics. | View FVIII Products |
| Related Target: GPIb | GPIbα (Platelet Receptor). Counter-target for platelet adhesion assays. | View GPIb Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shear-Dependent Binding Kinetics | Human/Mouse/Cyno VWF A1 Domain proteins available with >95% purity; Sequence Verified for ortholog binding studies under flow conditions. HEK293 expressed with native glycosylation for accurate conformational assessment. |
| Domain-Specific Drug Design (A1 vs A3) | Isolated Domain Proteins (A1, A3) strictly verified by mass spec; Eliminates cross-domain interference in screening. >95% purity, low endotoxin (<1EU/ug). |
| Multimerization Analysis | Lentivirus for Stable Cell Lines expressing full-length VWF; Preserves native conformation and multimer patterns. Endotoxin Controlled constructs ensure reproducible baseline. |
| Lack of Clinical Controls | Clinical Benchmark Nanobodies (Caplacizumab sequence) included as positive controls. |
| False Positives in Binding Assays | Validated siRNA included for specificity checks; VWFpp distinct antigen for biomarker calibration. |
Live VWF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VWF-targeted therapeutics is intensifying, with major players shifting focus from plasma-derived concentrates to precision biologics. Following the success of caplacizumab (first-in-class anti-VWF Nanobody) for acquired TTP, the pipeline has expanded into congenital TTP prophylaxis, VWF-modulating antithrombotics, and ADAMTS13 enhancers. As first-generation therapies establish safety profiles, the next wave of R&D is targeting domain-selective inhibition (A1 vs A3) and gene therapy corrections for von Willebrand Disease. Emerging approaches include subcutaneous formulations, longer half-lives, and precision aptamers designed to inhibit VWF-mediated thrombosis without increasing severe bleeding risks.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Nanobody (Anti-A1) | Sanofi (Ablynx) | Acquired TTP, Congenital TTP | A1 Domain Binding Assay (Need high-purity A1 antigen, Sequence Verified) |
| Monoclonal Antibody | Sanofi, Takeda | Thrombosis Prevention | Cross-species Reactivity (Need Cyno/Mouse A1 orthologs for PK/PD) |
| Recombinant VWF / Protein | Takeda, CSL Behring, Baxalta | Von Willebrand Disease (VWD) | VWFpp Ratio Analysis (Need distinct propeptide antigen for synthesis rate quantification); Clearance & Half-life eval (Need HEK293 Expressed native forms) |
| Aptamers | Bayer, Various Biotech | Thrombosis / Stroke | Selectivity Assay (Need precisely defined VWF fragments) |
| Gene Therapy | Biomarin, Takeda | Von Willebrand Disease | Multimerization Assay (Need Lentivirus-stable cell lines expressing full-length VWF) |
| ADAMTS13 Enhancer | Multiple Biotechs | Thrombotic Microangiopathy | Cleavage Assay (Need ADAMTS13 + VWF A2 domain substrate) |